Overtaken by their own success: management is reworking company plans mid-course because real business arrived bigger or
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management reveals own working assumptions overtaken by actual activity, bigger/faster/broader than assumed, and already changed something concrete, still catching up. Let's parse. Key candidate: Aimovig launch. Murdo says "one of the strongest launches... remarkable response... over 12,000 HCPs prescribe, over 100,000 patients starting since launch. Services set up to assist patients in gaining early access have been working to resolve requests from sizeable pent up demand. As we've addressed initial bolus of patient demand we expect prescription activity to moderate and normalize over coming weeks." This suggests demand exceeded? Did they say assumptions? They mention "pent up demand" and "bolus" and "services set up" - but did they say company's own assumptions overtaken? They say "we've been further energized by remarkable response" and "strongest launches I've seen." But no explicit "we expected less" or "our plans were overtaken." They did set up services to handle demand; now addressing bolus. Did they change something concrete? They extended DTC advertising in Q4. But that's marketing, not necessarily response to overshoot? They say "given debilitating nature... we've extended patient education campaign through DTC TV advertising in first part of Q4." That could be a concrete action due to low awareness, not due to overshoot. Also "we have first mover advantage." No mention of adding capacity, hiring, etc. They expect moderation. This seems like strong launch but not necessarily "company's own assumptions overtaken" with concrete changes. Other candidates: Repatha price cut? They announced new NDC at lower list price to improve access. This is a change in response to high copay/abandonment rates. But is that "reality outran assumptions"? They say "too many face hurdles due to high copay expenses. In light of this, last week we made important decision... launched new NDC at list price $5,850... should lower out-of-pocket costs and lower abandonment rate which is as high as 75%. Although lower price may impact Repatha sales near term, as plans update we expect positive impact on volume growth." This is a proactive change due to market access issues, not necessarily overshoot of demand. It's a response to a problem, not to demand exceeding assumptions.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
EMR · Q3 2021 → YESThe question is whether management reveals that the company's own working assumptions have been overtaken by actual events, they've already changed something concrete, and they're still catching up. ...YES The transcript shows management confirming that actual operating activity (sales/orders growth, demand recovery, project wins) has outrun their own prior expectations and plans for the quarter and year. They explicitly note sales/orders "ahead of our expectations," "exceeding our management expectations," and a "V-shaped demand recovery" plus 26% trailing orders that accelerated beyond what was assumed. In response, they have already taken concrete actions: ramping up capacity at plants in the U.S.
MNKD · Q4 2023 → YESThe question is whether management reveals that the company's own working assumptions have been overtaken by actual events, they've already changed something concrete, and they're still catching up. ...YES The transcript shows management confirming that Tyvaso DPI demand and production have run ahead of their own earlier assumptions: the launch was “under-forecast,” actual patient uptake and volumes exceeded what they had planned, and they had to “work incredibly hard” and add capacity (high-speed fill line) to keep up 100 % of demand. They have already acted by completing the new line qualification, starting PPQ runs, and ramping production “much higher” volumes in Q1/Q2.
AOSL · Q2 2018 → YESThe question is whether management reveals that the company's own working assumptions have been overtaken by actual events, they've already changed something concrete, and they're still catching up. ...YES The transcript shows management describing a clear upward surprise in demand for new products that has already outrun their existing capacity plans ("demand for our new products has increased in the last year or so... capacity constraints have caused us to forgo potential revenue... tens of millions of dollars"), with the Chongqing JV built specifically to address it.